Therapies Against COVID-19: a Running to a Treatment

ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan
{"title":"Therapies Against COVID-19: a Running to a Treatment","authors":"ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan ","doi":"10.34178/jbth.v3i2.125","DOIUrl":null,"url":null,"abstract":"There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus. \n ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"62 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34178/jbth.v3i2.125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus.  
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对COVID-19的治疗:一种治疗方法
目前还没有针对COVID-19的特异性药物或治疗方法。自大流行开始以来,科学家们一直在努力发现一种可以治疗这种疾病的药物或疗法。到目前为止,我们发现的是一种药物和疗法的结合,可以减轻这种疾病对人体的影响,以及如何更好地管理病人。在本文中,我们试图加入新的发现,并介绍了对抗SARS-CoV-2的药物和疗法及其机制。我们展示了免疫调节剂、杀寄生虫剂、抗病毒药物(主要是雷姆德西韦)、抗疟疾药物、主要是IL-6作用的抗细胞因子药物、风湿病药物、细胞受体抑制剂、抗炎药物,特别是皮质类固醇(地塞米松)、抗生素(阿奇霉素)、抗血栓形成药物、血液衍生物疗法和目前用于COVID-19的替代疗法。此外,我们还列出了推荐小组治疗指南[NIAID-RML (USA)]中提出的新疗法临床试验的主要结果。我们检索了主数据库(PubMed/Medline、Elsevier Science Direct、Scopus、Isi Web of Science、Embase、摘录Medica、UptoDate、丁香、爱思唯尔新型冠状病毒资源目录)和高影响力国际科学期刊(Scimago Journal和Country Rank - SJR - and Journal Citation Reports - JCR)的数据,如the Lancet、Science、Nature、the New England Journal of Medicine、Physiological Reviews、Journal of American Medical Association、Plos One、《临床调查杂志》,数据来自美国疾病控制中心(CDC)、美国国立卫生研究院(NIH)、美国国家过敏和传染病研究所(NIAID)和世界卫生组织(WHO)。我们之前按照这个顺序选择了meta分析、系统综述、文章综述和原创文章。我们使用了2020年3月至6月的302篇文章,使用了以下术语:冠状病毒、SARS-CoV-2、新型冠状病毒、武汉冠状病毒、严重急性呼吸综合征、2019- ncov、2019新型冠状病毒、n-CoV-2、covid、n-SARS-2、covid、冠状病毒、冠状病毒、免疫调节剂、抗寄生虫剂、抗病毒药物、抗疟疾药物、抗血栓形成和抗细胞因子、抗炎药、风湿病药物、细胞受体抑制剂、抗生素、血液衍生物疗法和替代疗法。使用工具MeSH(医学主题标题)、AND、OR和字符[,",;/。,确保最佳的复习题目。我们的结论是,尽管没有针对COVID-19的治疗方法或药物,但联合治疗可以帮助减轻疾病的影响,帮助免疫系统对抗病毒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Proposing a Method for Assessing Fuel Consumption and Pollutants Emissions with the Use of Continuously Variable Transmission in Town Cars The Paradox and Dynamic Betweem Sustainable Development and Corporate Performance Water Quality Assessment Using Daphnia: A Brief Review Essential Oil Steam Distillation: Manufacturing 4.0 Applications of Metabolities Extracted from Macroalgae to Fight Neglected Diseases in Brazil
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1